9600万美元!眼科成BD新热土,信达、奥赛康领跑国产眼科双抗赛道!

求实药社
Oct 24, 2025

近日,奥赛康子公司AskGene Pharma与Visara公司达成授权许可协议,将其自主研发的眼科双抗ASKG712(靶向VEGF/ANG-2抗体)在大中华地区、新加坡、泰国、马来西亚、印度尼西亚、越南、韩国及印度市场的独家权益授予Visara。根据协议,AskGene将获得700万美元首付款,未来还有望获得最高不超过8900万美元的里程碑付款,以及产品销售的特许权使用费。而在一个月前,信达生物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10